$ELAN

O'Neill Shiv purchased $94K of ELAN

O'Neill Shiv (GC AND CORP SEC) purchased 3,998 shares of Elanco Animal Health Inc (ELAN) at $23.58 on 2026-08-18.

Original reporting
SEC EDGAR · O'Neill Shiv
Published Aug 18, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELAN
Bullish
medium confidence
Mentioned
$ELAN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELANBullishLow
01

Why it matters

The only new fact is the insider’s purchase details (shares, price, total value, and post-transaction holdings). There is no accompanying company guidance, operational update, or regulatory/legal development.

02

Market read

Traders may note the insider buy as a mild sentiment input, but it is unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

The filing does not state a 10b5-1 plan and provides no context on motivation, timing, or whether the insider has ongoing trading patterns.

Relevance 4/10Novelty 3/10Timing: filed on 2026-08-18, after-hours SEC EDGAR timestamp

Background

This is an SEC Form 4 insider transaction disclosure for Elanco Animal Health Inc.

Company-level read

Ticker impact

$ELANBullishMedium confidence
Context

Elanco Animal Health insider O'Neill Shiv filed a Form 4 open-market purchase of 3,998 shares at $23.58 on 2026-08-18.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically small for routine Form 4 buys.

Evidence & confidence

Form 4 insider purchases can be read as confidence, but the article provides no new operational or financial information, and the transaction is not described as part of a major event or 10b5-1 plan.

Market effects

No sector-wide read-through is provided beyond a single insider transaction.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be routine liquidity or diversification activity and may not reflect a new fundamental outlook.

Key entities

  • Elanco Animal Health Inc

    Subject of the Form 4 insider transaction disclosure.

  • O'Neill Shiv

    Reported officer (GC and Corp SEC) who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELANLow

Wrap up: Elanco expands Kansas biologics plant, and other news

Elanco Animal Health completed a $120 million expansion of its biologics plant in Kansas, increasing capacity fourfold. The company plans to invest an additional $30 million by 2028, aiming for unconstrained supply of its dermatology product Befrena by early 2027, as demand is twice expectations.

$ELANLow

Elanco completes $120 million expansion of its Kansas biologics plant

Elanco Animal Health completed a $120M expansion of its Kansas biologics plant, increasing production capacity 4x. The site now serves as the company's center for monoclonal antibody (mAb) manufacturing, with plans for an additional $30M investment by 2028. Elanco acquired the site in 2021 and has since grown its workforce from 30 to over 200 employees. The expansion supports products like Trutect and Befrena, with demand for the latter exceeding expectations.

$ELANMed

Elanco rating upgraded by Fitch on deleveraging progress

Fitch Ratings upgraded Elanco Animal Health’s (NYSE:ELAN) Long-Term Issuer Default Rating to BB+ from BB and raised senior secured to BBB- from BB+ and senior unsecured to BB+ from BB, with a stable outlook. Fitch cited balance-sheet deleveraging, share gains, and cash flow. It projects EBITDA leverage below 3.5x, debt down about $650M since 2024, and free cash flow rising from $345M (2026) to ~$575M (2028).